^
    16h
    SKB264-ANLO: Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, China Medical University, China
    New P2 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    2d
    Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation. (PubMed, Front Immunol)
    An elderly male diagnosed with Stage IV LUAD achieved sustained stable disease (SD) and symptomatic improvement through a sequential therapeutic strategy, including platinum-based chemotherapy followed by the PD-1 inhibitor sintilimab combined with anti-angiogenic agents (apatinib or anlotinib). This case demonstrates that while ICIs can provide exceptional long-term benefits in advanced NSCLC, particularly in patients with highly immunogenic mutation profiles, they may also trigger late-onset fatal irAEs. Our findings underscore the imperative for close, long-term metabolic surveillance throughout the course of immunotherapy, regardless of treatment duration or radiological stability.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS G12C • KRAS G12
    |
    Focus V (anlotinib) • Tyvyt (sintilimab) • AiTan (rivoceranib)
    2d
    ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer. (PubMed, World J Surg Oncol)
    The ERBB2 I655V mutation may be associated with improved treatment response to immunotherapy in gallbladder cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TYK2 (Tyrosine Kinase 2)
    |
    PD-L1 expression • HER-2 overexpression • HER-2 mutation
    |
    Focus V (anlotinib) • AiRuiKa (camrelizumab)
    3d
    Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=412, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • gemcitabine • Focus V (anlotinib) • Andewei (benmelstobart)
    3d
    Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway. (PubMed, Biochem Biophys Rep)
    To overcome these limitations, we systematically evaluated the synergistic Combination effects of three drug candidates, OTX-015 (BET inhibitor), Metformin (metabolic regulator), and Anlotinib (multitargeted tyrosine kinase inhibitor), with Chidamide. Chidamide and Anlotinib synergistically inhibit Hippo signaling pathway, which reveals a novel "dual epigenetic kinase targeting" strategy for the treatment of T-ALL. Future studies should validate these findings in vivo and investigate the impact of the metabolic microenvironment on therapeutic efficacy.
    Journal
    |
    CTGF (Connective tissue growth factor)
    |
    Focus V (anlotinib) • Epidaza (chidamide) • birabresib (OTX015) • metformin
    5d
    ANCHOR: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=748, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin
    6d
    Beromuzumab Plus Anlotinib Combined with SBRT for Patients with Hepatocellular Carcinoma Failing First-Line Targeted Therapy:A Single-Arm, Multicenter Clinical Study (ChiCTR2600117101)
    P=N/A, N=29, Not yet recruiting, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New trial
    |
    Focus V (anlotinib)
    6d
    A Prospective, Single-arm, Exploratory Study of Aipalolitovorilimab Combined with Anlotinib and Low-dose Radiotherapy in the Treatment of Advanced Esophageal Cancer with Prior Immunotherapy Failure. (ChiCTR2600116202)
    P=N/A, N=30, Not yet recruiting, Anhui Provincial Cancer Hospital.; Anhui Provincial Cancer Hospital
    New trial
    |
    Focus V (anlotinib)
    6d
    Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study (ChiCTR2500114484)
    P=N/A, N=34, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    6d
    A phase II clinical study on the efficacy and safety of anlotinib combined with oral etoposide capsules as first-line treatment for extensive-stage small cell lung cancer (ESSCLC) (ChiCTR2500112982)
    P=N/A, N=39, Not yet recruiting, The Pearl River Hospital of Southern Medical University; The Pearl River Hospital of Southern Medical University
    New trial
    |
    Focus V (anlotinib) • etoposide oral
    6d
    A Retrospective Study on Efficacy Evaluation of Anlotinib Combined with Temozolomide in the Treatment of Recurrent Glioma Based on Real-World Data (ChiCTR2500112913)
    P=N/A, N=144, Recruiting, The First Affiliated Hospital of Army Medical University of the Chinese People's Liberation Army; The First Affiliated Hospital of Army Medical Univer
    New trial
    |
    Focus V (anlotinib) • temozolomide
    6d
    Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus (ChiCTR2500112169)
    P=N/A, N=27, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New trial
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)